ArticleHealth care science2023
Evolution and major changes of the diagnosis and treatment protocol for COVID-19 patients in China 2020-2023.
Article in Health care science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy adjustments.Frontiers of medicine · 2024Pooled it
- Evaluating Biomedical Feature Fusion on Machine Learning's Predictability and Interpretability of COVID-19 Severity Types: Model Development, Interpretation, and Validation.JMIR formative research · 2026Article
- Symptoms, risk factors, and health outcomes of long COVID in the United Arab Emirates.Scientific reports · 2026Article
- Article
- Hospital readmission rates and factors due to COVID-19 reinfections: a registry-based cohort study in Brazil (2020-2022).BMC public health · 2025Article
- Review
- Article
- Novel method for the identification of circulating SARS-CoV-2 variants and clinical characteristics of patient infection with SARS-CoV-2 variants in Central China.Frontiers in cellular and infection microbiology · 2025Article
- The critical role of health policy and management in epidemic control: COVID-19 and beyond.Infectious medicine · 2024Article
- Innovative public strategies in response to COVID-19: A review of practices from China.Health care science · 2024Review
- A cross-sectional survey on COVID-19 phobia and its influencing factors among undergraduate nursing students.BMC nursing · 2024Article
- Epidemiological and Clinical Characteristics Associated with COVID-19 Severity Among Hospitalized Patients in the United Arab Emirates: A Retrospective Multicentre Study.Journal of epidemiology and global health · 2024Observational
- Biases in COVID-19 vaccine effectiveness studies using cohort design.Frontiers in medicine · 2024Review
- Rate, risk factors, and clinical outcomes of SARS-CoV-2 reinfection vs. primary infection in readmitted COVID-19 patients in Iran: a retrospective cohort study.Frontiers in public health · 2024Article
- Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era.Cancer medicine · 2023Article
- Evolution and major changes of the diagnosis and treatment protocol for COVID-19 patients in China 2020-2023.Health care science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the identification of the first case of pneumonia of unknown cause in 2019, the COVID-19 pandemic has spread the globe for over 3 years. As the most populous country in the world, China's disease prevention policies and response plans concern the health of the country's 1.4 billion people and beyond. During the course of the pandemic, scientific research has been accumulated and given evidence-based support to the official guidance of COVID-19 management. The National Health Commission of China have compiled, published, and updated a total of 10 versions of the "Diagnosis and Treatment Protocol for COVID-19 Patients" to better inform clinical practitioners and staff to effectively screen, diagnose, manage, treat, and care for cases of severe acute respiratory syndrome coronavirus 2 infection. This paper compares and summarizes each version of the protocol in terms of etiology and epidemiology, clinical manifestation and diagnosis, treatment and nursing, disease control and management, presenting detailed changes, additions, deletions, and refinement of the protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.